Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Type B insulin-resistance syndrome belongs to the group of extreme insulin-resistance syndromes (which includes leprechaunism, the lipodystrophies, Rabson-Mendenhall syndrome, and type A insulin resistance syndrome) and occurs in the context of immune dysfunction.
Biomarker and diagnostic research for insulin-resistance syndrome type B has been reported in the published literature.
Estimated prevalence: Unknown (Unknown prevalence).
No clinical trials have been registered for insulin-resistance syndrome type B.
201 publications have been identified in PubMed for insulin-resistance syndrome type B. Kisho has analyzed 74 by research type. Research spans Basic Science / Preclinical (51%), Review / Meta-Analysis (19%), and Clinical Trial Publication (11%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 38 | 51% |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 1:57 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Research summaries |
14 |
19% |
Clinical study results | 8 | 11% |
Disease patterns and progression | 6 | 8% |
Patient case studies | 5 | 7% |
Other research | 1 | 1% |
Testing and diagnosis research | 1 | 1% |
New treatment approaches | 1 | 1% |
Naidoo P (2026). [PMID: 41767203](https://pubmed.ncbi.nlm.nih.gov/41767203/). *JCEM Case Rep*. [Case Report / Case Series]
Tiash S (2026). [PMID: 41812649](https://pubmed.ncbi.nlm.nih.gov/41812649/). *Cell Metab*. [Basic Science / Preclinical]
Egawa E (2026). [PMID: 41451857](https://pubmed.ncbi.nlm.nih.gov/41451857/). *J Diabetes Investig*. [Case Report / Case Series]
Xenos D (2026). [PMID: 41275975](https://pubmed.ncbi.nlm.nih.gov/41275975/). *Ageing Res Rev*. [Review / Meta-Analysis]
Maracle B (2026). [PMID: 41319219](https://pubmed.ncbi.nlm.nih.gov/41319219/). *Alimentary pharmacology & therapeutics*. [Review / Meta-Analysis]
Liskiewicz D (2026). [PMID: 42056522](https://pubmed.ncbi.nlm.nih.gov/42056522/). *Nature*. [Basic Science / Preclinical]
Arslanian S (2026). [PMID: 41296499](https://pubmed.ncbi.nlm.nih.gov/41296499/). *Diabetes Care*. [Clinical Trial Publication]
Manda S (2026). [PMID: 41574820](https://pubmed.ncbi.nlm.nih.gov/41574820/). *J Diabetes Investig*. [Case Report / Case Series]
Zhu Y (2025). [PMID: 40186867](https://pubmed.ncbi.nlm.nih.gov/40186867/). *Cell Rep*. [Basic Science / Preclinical]
Wimer LA (2025). [PMID: 41086114](https://pubmed.ncbi.nlm.nih.gov/41086114/). *Cell Rep*. [Basic Science / Preclinical]